Most users report meaningful changes at moderate doses (2-4mg weekly), with less clear additional benefit at higher doses specifically for alcohol effects
GLP-1 agonist medications can slow digestion, reduce appetite, and improve insulin response
Tirzepatide typically begins low and escalates every four weeks, while retatrutide may have a faster dose escalation period
All pharmacokinetic data cited are from the published Phase 2 clinical trial and supporting literature
[DOI] [PMC free article] [PubMed] [Google Scholar] 91.Bak M.J., Wewer Albrechtsen N.J., Pedersen J., Knop F.K., Vilsbll T., Jrgensen N.B., et al
That prompted Katz to post a question on a national neuro-ophthalmology listserv to see if his colleagues were seeing similar things in their patients